HIGH-DOSE CYCLOPHOSPHAMIDE AND HIGH-DOSE VP-16-213 FOR RECURRENT OR REFRACTORY SMALL-CELL LUNG-CANCER - A PHASE-II STUDY

Pieter E. Postmus*, Nanno H MULDER, Hilly G De Vries- Hospers, Paula O.M Mulder, Annelies Maas, Aaf F. Meinesz, Dirk. Th Sleijfer, Elisabeth G.E. De Vries

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    6 Citations (Scopus)

    Abstract

    n nine patients with recurrent or refractory small cell lung cancer a phase II study with high-dose cyclophosphamide and high-dose VP 16-213 with autologous bone marrow transplantation was performed. The regimen used was based on a previously reported phase I study. In eight of the nine evaluable patients a response was seen (six PR and two CR). One patient died of treatment related toxicity. Infection is the most important toxicity. The response duration was short. This combination is a suitable "late intensification' regimen for patients with minimal residual disease after standard dose induction chemotherapy.
    Original languageEnglish
    Pages (from-to)1467-1470
    Number of pages4
    JournalEuropean journal of cancer & clinical oncology
    Volume21
    Issue number12
    DOIs
    Publication statusPublished - Dec-1985

    Cite this